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Objectives: The aim of this study was to compare, at delivery, the cord blood 
mononuclear cells of infants with severe hemolytic disease who received intrau­
terine transfusion (IUT) therapy with the cord blood mononuclear cells of healthy 
rionimmunized control neonates.
Study design: The expression of leukocyte markers on CBMNC of 14 lUT-treated 
and 18 control neonates was analyzed by means of a panel of well-defined 
monoclonal antibodies and flow cytometry.
Resuits: Patients with severe hemolytic disease requiring IUT treatment displayed 
significant altered expression of some leukocyte markers when compared with 
control subjects. The circulating CD34+ progenitor cells were significantly in­
creased in comparison with cord blood of nonimmunized neonates. lUT-treated 
patients also showed a statistically significant decrease in natural killer (NK) cell 
associated markers (CD16, CD57, and CD69), which correlated with a lower ex­
pression of CD56. In these patients an increased expression of CD3/CD45RO and 
CD3/CD5 was also noted. Although these latter alterations were statistically sig­
nificant in a single-parameter analysis, the significance disappeared after multi­
param eter analysis because of a loss of statistical power.
Conclusions: Compared with nonimmunized healthy newborn infants, patients 
who underwent IUT also exhibited a down-regulation of NK cells and NK cell as­
sociated markers, as well as increased numbers of CD34+ progenitor cells. <J Pe- 
d ia trl 997; 130:718-24)
Intrauterine transfusion therapy was introduced in 1963 to 
treat severe hemolytic disease of the fetus.1 Since the intro­
duction of IUT, improvement in management of pregnancies 
complicated by alloimmunization, technical achievements in 
blood transfusion therapy, and access to the umbilical cord 
by intravascular puncture under ultrasound guidance have
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reduced the complications concomitant with this therapy. 
These developments have resulted in more than 85%
See related articles, pp. 686, 689, and 695.
CBMNC Cord blood mononuclear cells
HLA Human leukocyte antigen
IUT Intrauterine transfusion
NK Natural killer [cells]
survival of the affected fetuses.2,3 Reduction of the number 
of leukocytes by filtration and irradiation of the IUT unit
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have abolished graft-versus-host disease. Both extensive 
donor counseling and the screening of donor blood have re­
sulted in diminished transmission of viral diseases, while 
adjustment of the hematocrit of the IUT to 80% (0.8), 
reduced the volume load given to the fetus.
Although thousands of fetuses have received IUTs world­
wide, the effect of IUT therapy on the immune system has 
not yet been investigated. The few available follow-up stud­
ies mainly concern the effects of this treatment on the sen­
sorineural outcome.4*5 The effect of IUT on the developing 
immune system is intriguing because normal development 
takes place in an almost alio ant igen-free environment dur­
ing which the fetal immune system is mainly confronted with 
self-antigens and maternal antigens. Introducing alloanti- 
gens by IUT may induce either tolerance or alloreactivity 
against donor antigens.6'10 Moreover, blood transfusions can
also affect the immune system not restricted by the major0
histocompatibility complex, which could be attributed to an 
increased susceptibility to infection.11,12
To evaluate the effect of IUT on the composition of the 
peripheral cord blood mononuclear cells' repertoire with re­
spect to the expression of cell surface markers defining sev­
eral leukocyte subsets and activation markers, we compared 
lymphocyte CBMNC of 14 IUT-treated patients with 18 
control neonates.
%
M E T H O D S
Patients and control subjects. Fourteen patients received 
unrelated-donor erythrocytes to treat severe hemolytic dis­
ease of the fetus. On average, the first IUT was performed 
at 27 weeks of gestation (range, 19 to 34 weeks). Before the 
first IUT the mean hemoglobin level of the fetuses was 3.5 
mmol/L (range, 1.2 to 6.6 mmol/L). The mean number of 
IUTs was 3 (range, 1 to 6), and deliveries took place at 37 
weeks of gestation (range, 32 to 39 weeks). In one case the 
infant was born by cesarean delivery; the other 13 infants 
were born by vaginal delivery.
Eighteen untreated neonates were used as control subjects. 
All these infants were born by vaginal delivery at an aver­
age of 40 weeks of gestation (range, 38 to 41 weeks).
Preparation of IUT. The IUT was prepared from fresh 
(<24 hours old) donor erythrocytes that were compatible 
with maternal erythrocyte antibodies. Donor blood was col­
lected in citrate-phosphate-dextrose solution. Erythrocytes 
were filtered after buffy-coat removal and contained fewer 
than 5 x 106 leukocytes per unit. The hematocrit was 
adjusted to approximately 85% (0.85) by using 0.9% saline 
solution. Erythrocytes were irradiated with 25 Gy and 
administered within 3 hours after preparation.
Collection of cord blood samples. Cord blood (30 to 50 
ml) was obtained from the umbilical vein immediately after 
delivery and collected in heparinized tubes. CBMNC were
isolated by Ficoll-Hypaque density gradient sedimentation 
within 12 hours after collection. To exclude contamination 
of cord blood with donor leukocytes, we analyzed only the 
CBMNC of those infants whose time between the last IUT 
and delivery was at least 2 weeks.
Monoclonal antibodies. To determine the expression of 
leukocyte cell markers, we used either fluorescein isothyo­
cyanate-, phycoerythrin-, or peridinin chlorophyll protein 
conjugated monoclonal antibodies. When none of these 
conjugated monoclonal antibodies was available, unconju­
gated antihuman monoclonal antibodies were used and flu­
orescein isothyocyanate or phycoerythrin goat antimouse 
immunoglobulin was added after incubation with the un­
conjugated monoclonal antibodies. All monoclonal antihu­
man antibodies (CD1, CD3, CD4, CD8, CD16, CD19, 
CD20, CD25, CD34, CD45, CD45RA, CD45RO, CD56, 
CD57, CD69, anti-HLA-DR) were purchased from Bee ton 
Dickinson UK Ltd. (Oxford, England).
Staining procedures. For each test, 5 x 105 CBMNC 
were incubated with 20 pi (12 mg/ml) pooled human immu­
noglobulin for 10 minutes at room temperature, to prevent 
nonspecific staining, and then washed and incubated with 50 
jil monoclonal antibodies for 30 minutes at 4° C. After in­
cubation, the cells were washed twice with 0.9% saline so­
lution containing 1% bovine serum albumin. If unconjugated 
monoclonal antibodies were used, 50 jul goat antimouse im­
munoglobulin labeled with phycoerythrin or fluorescein 
isothyocyanate was subsequently added and incubated for 30 
minutes at 4° C. After the second incubation the cells were 
washed twice. When a combination of conjugated mono­
clonal antibody and unconjugated monoclonal antibodies 
were used, incubation with the unconjugated monoclonal 
antibody was first performed, followed by blocking with 2% 
normal mouse serum before the addition of the conjugated 
antibody. After the labeling procedure, 3 ml Becton Dickin­
son lysing solution was then added and left for 10 minutes 
at room temperature to reduce the number of erythroblasts 
and erythrocytes. In some newborn infants a high number of 
erythroblasts is present in cord blood, especially in patients 
undergoing hemolysis. Because erythrocyte lysing solution 
does not completely remove erythroblasts from cord blood, 
it remains contaminated with cells of the erythroid lineage.13 
To establish reliable values for different CBMNC subsets, 
we corrected the expression of the different cell markers for 
the percentage of glycophorin A expressing (erythroid Iin-
*
eage) and CD45'h mononuclear cells present in the gated cell 
population.
Flow cytometry. Either one-, two-, or three-color flow 
cytometry was performed with a FACS can flow cytometer 
(Becton Dickinson, Mountain View, Calif.) and gated on a 
forward angle versus 90-degree light scatter and the use of 
back-gating with cluster designation 45 (CD45) and CD 14
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Table. Hematologic parameters and lymphocytes subsets on CBMNC at delivery
■
IUT-treated neonates Contro! subjects
Mean Range Mean Range P
Hematologic parameters*
Hemoglobin/(mmoI/L) 6.3 3.6-8.9 9.8 8.4-10.7 <0.0001
Hematocrit (%) 30,0 18-42 49.0 41-59 <0.0001
Leukocytes (xl09/L) 15,2 5.6-24.7 16.8 8.8-34.3 NS
Reticulocytes (xlO/L) 0.03 0.00-0.18 0.0 0.00-0.06 NS
Erythroblasts (xlO/L) 80.0 2-574 6.0 0-28 0.0263
Platelets (xlO/L) 173.0 Í 6-383 235.0 180-322 0.0375
Lymphocytes (_%) 31.0 12-52 29.0 12-45 NS
Monocytes (%) 9.0 4-13 9.0 3-19 NS
Lymphocyte Subselt,i 
NK cells
CD57 0.0 0-0 1.4 0-6 0 .0 0 0 1*
T cells
CD1 3.5 . 0-22 1.2 0-7 NS
CD3 49.0 30-80 51.0 33-70 NS
CD3/CD4 31.0 7-57 33.0 13-40 NS
CD3/CD8 20.0 6-33 19.0 13-35 NS
CD3/CD45 RO 43.0 0-74 47.0 14-86 NS
B cells
CD19 19.0 8-29 16.0 9-23 NS
CD20 20.0 7-31 15.0 8-32 NS
CD19/CD5 7.0 3-10 6.0 2-12 NS
Activation markers
CD25 2,9 0-30 2.9 1-15 NS
HLA-DR 36.0 14-63 36.0 25-50 NS
Results expressed as mean percentage and range percentage of expression of CD45* cells after subtraction of glycophorin A-expressing cells. The numbers dis­
played in bold typeface resemble statistical significance in comparison with those of control subjects (p <0.05).
N S , Not significant.
*IUT-treated neonates; n = 12; control subjects: n « 18, 
tIUT-treated neonates: n = 14; control subjects: n -  18,
^Corrected p value after multiparameter analysis = 0,0016,
staining. A minimum of 10,000 gated events were analyzed 
for each sample.
Leukocyte and differential cell counts. Leukocyte and 
differential cell counts were performed with a Hemalog 
one-cell counter (Technicon Instalments Corp., Tarry town, 
N.Y.). When the analysis revealed extremely low numbers 
of a particular parameter, a differential manual count was 
performed.
Statistical analysis. The data on the IUT-treated patients 
and on the untreated neonates wete compared with the two- 
tailed nonparametric unpaired Mann-Whitney test. Results 
were also corrected for the number of parameters analyzed 
by using the method of Edwards.14 A p  value less than 0.05 
was considered statistically significant.
R E SU L T S
Hematologic values. The hematologic values of cord 
blood from 12 IUT-treated patients and 18 healthy control 
subjects are summarized in the Table. As expected, the he­
matocrit and hemoglobin levels in patients with hemolytic
disease were significantly lower than in untreated control 
subjects because of the continuing breakdown of fetal red 
cells by maternal antibodies and the limited lifespan of 
transfused donor erythrocytes. Consequently, cord blood of 
the IUT-treated neonates contained more erythroblasts and 
reticulocytes because of the compensatory production of red 
cells. Both the absolute number of leukocytes in both groups 
and the leukocyte differentiation were similar. Five IUT- 
treated neonates had thrombocytopenia (platelet count, 
<150 x 109/L), which resulted in a significantly lower mean 
platelet count in the IUT-treated patients.
Mononuclear cells and immunophenotyping. The ex­
pression of cell surface markers on CBMNC of 14 IUT- 
treated and 18 non-IUT-treated neonates is summarized in 
the Table.
Hematopoietic progenitor cells. The percentage of pro­
genitor cells analyzed with anti-CD34 monoclonal antibody 
was significantly higher in the IUT group (3.1%) than in the 
control group (1%) (Figure, A).
NK cells. In comparison with cord blood of untreated ne-
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Fig. 1. Individual ( 0 )  and mean fhorizontal bars) percentage of expression of CD34 (A), CD56 (B), CD 16 (C), CD3/ 
CD5 (D), CD3/CD45RO (E), and CD69 (F) on CBMNC of IUT-treated patients (n =r 14) and untreated control subjects 
(n = 18). p-corr, Corrected p value for the number of parameters analyzed (17). In 11 IUT-treated patients (n = 11), the ex­
pression of CD69 (F) was 0%.
onates, the cord blood of IUT-treated fetuses expressed sta­
tistically significant lower numbers of CD56'h cells before 
multiparameter correction (Figure, B). There was a signifi­
cant decrease in cells expressing Fc7 -receptor III (CD 16) in 
the IUT group (Figure, Q .  CD57 was expressed in low 
numbers on CBMNC of the control subjects (1.4%) and was 
almost undetectable in IUT-treated patients (Table).
T cells. The expression of CD4 and CD 8 on T cells was 
similar in both groups (Table). Coexpression of CD3 and 
CD5 (Figure, D) was 34% in the IUT-treated group and sig­
nificantly higher than in the control subjects (22%). The two 
isoforms of CD45 that distinguish between “ naive” and
“ memory” T cells were analyzed by using anti-CD45RA 
and anti-CD45RO. CD3+ CBMNC coexpressing CD45RO 
(Figure, E) were significantly increased in the IUT group 
(8%) in comparison with untreated neonates (2 %). It should 
be noted that these apparently significant differences were 
lost after correction for the number of parameters analyzed 
because of a loss in statistical power* The expression char­
acteristics of both CD45RO and CDS on CD3+ cells in con­
trol subjects and in IUT-treated patients revealed a wide dis­
tribution.
B cells. The percentage of B cells (Table), as defined by 
the expression of CD19 and CD20, was slightly elevated in
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the IUT group (19% and 20%) in comparison with the con­
trol subjects (16% and 15%). The percentages of B cells ex­
pressing CD5 were evenly distributed in IUT-treated patients 
and control subjects (7% vs 6%). HLA-DR was expressed 
on nearly all B cells in both groups.
Activated cells. We did not observe any difference in ex­
pression of CD25, the low-affinity interleukin-2 a-chain re­
ceptor, in both groups (Table). However, the time between 
the last transfusion and birth was longer than 2 weeks, which 
was probably too long to measure an effect on these 
transiently expressed molecules. Moreover, the percentage 
of HLA-DR* CBMNC was similar in both groups (Table). 
Expression of CD69 was significantly lower after IUT treat­
ment and in most cases absent in the IUT group (Figure, F).
D IS C U S S I O N
The normal distribution of lymphocyte subsets in cord 
blood of healthy fetuses, neonates, and young children has 
been extensively studied.15"28 In general, distribution, ex- 
pression, and range of expression of cell surfaec markers in 
fetuses and neonates differs from those in adults. Neonatal 
mononuclear cells express more naive CD4+ T cells (>90% 
CD45RA+) than do those of adults (40% to 60%) and more 
immature CD5+ B cells (30% vs 5%). Neonates are gener­
ally physiologically immunodeficient concerning immuno­
globulin production, class switch, and magnitude of the al- 
loimmune response.29"31 The observed maturational and de­
velopmental changes occurring in lymphocyte populations 
during life can be largely attributed to antigenic challenges.26
Severe anemia in fetuses with hemolytic disease requiring 
IUT therapy results in non selective lymphopenia propor­
tional to the degree of anemia.32 To determine whether IUT 
treatment resulted in reversal of these changes or imposed 
additional effects on lymphocyte subsets after exposure to 
donor alio antigens, we compared CBMNC of IUT-treated 
patients with those of control neonates. For this purpose we 
used a broad selection of monoclonal antibodies, which de­
fines various subsets of mononuclear cells. This limited the 
conclusions that could be drawn from this relatively small 
study population because we had to correct the statistical 
significance for the number of monoclonal antibodies tested.
The significant increase of CD34+ progenitor cells in 
IUT-treated patients may reflect the compensatory hemato­
poietic stimulation in favor of the erythroid cell lineage in the 
fetuses with hemolytic anemia.33“35
Although the statistical significance of the reduction in
«
CD56-expressing cells in the IUT-treated group disappeared 
after correction for the number of parameters analyzed, an 
overall decrease in expression of this marker was observed. 
The statistically significant lower expression of CD 16 in this 
group of patients was probably the result of down-regulation 
in addition to diminished numbers of NK cells. The
published observations on the expression of CD56 and CD 16 
on CBMNC of healthy newborn infants show a wide range, 
and both increased and decreased values have been found 
when compared with those for adults.18“28 The expression of 
CD57 (subset of NK cells with low natural killer activity) is 
low in neonates, and expression increases slowly throughout 
life.23'28 A large percentage of healthy neonates (63%) have 
severely reduced NK function in vitro, corresponding to a 
low expression of CD56 on CBMNC, whereas the expres­
sion of CD 16 and that of CD57 were found to be within nor­
mal ranges.28 We found the expression of CD57 to be low 
in control subjects and almost absent in the IUT group. In 
addition, the diminished expression of the early activation 
marker CD69 in the IUT group could be due to reduced 
numbers of NK cells as well as active down-regulation of this 
marker, because this marker was expressed only on NK cells 
and was virtually absent on T and B cells in both groups (data 
not shown). In general, a clear tendency toward down-reg­
ulation of NK cells and a statistically significant decrease in 
NK cell associated markers was observed in the IUT-treated 
patients. This might reflect reduced NK cell activity and a 
more immature profile of NK cells in these patients.
In patients witii hemolytic disease who received IUT 
treatment, the number of leukocytes, leukocyte differentia­
tion, and relative percentages of T and B cells are compara­
ble to those of control patients. Within die T-ceil lineage, the 
percentage of CD4+ and CD8+ T cells is similar in both 
groups. CD5-exp res sing T cells represent 95% of the circu­
lating adult T cells. Both in IUT-treated patients and in un­
treated control subjects, the expression of CD5 on T cells was 
reduced and represents 68% and 43% of circulating T cells 
in the two groups, respectively. This difference may reflect 
a more mature pattern of expression on T cells in the IUT- 
treated group (Figure, D). Another reflection of premature 
T-cell maturation is the increased coexpression of CD45RO 
on CD3+ cells in these patients, suggesting a higher number 
of “memory” T cells induced in utero (Figure, E). An in­
creased percentage of more than 17% of CD45RO* T cells 
in neonatal blood was proposed as a marker for the presence 
of a congenital infection.36 None of the neonates in this study 
had any signs or symptoms of a congenital infection at birth. 
Therefore the increased number of CD45RO+ T cells is 
probably due to an al loimmune response to the IUT, but this 
increase was not observed in all patients. This might be the 
result of variations in numbers of leukocytes transfused, 
HLA-DR sharing between donor and fetus, or other anti­
genic differences related to the transfusion.
The method of delivery and the length of gestation have 
profound effects on leukocyte subpopulations.37’38 Consid­
ering these factors, which can influence lymphocyte sub­
populations in neonates, it is difficult to distinguish the ob­
served effects from specific transfusion effects. However,
the increased expression of CD3/CD45RO+ cells is likely to 
be the result of an antigenic challenge in utero. The decreased 
numbers of NK cells and associated cell markers are in 
agreement with the earlier study of Thilaganathan et al.32 
They also observed diminished numbers of T cells (CD4+ 
and CD8+) and B cells before the start of IUT therapy in pa­
tients with hemolytic disease. These differences in T and B 
cells were even more apparent earlier in gestation, probably 
correlating with the severity of the disease. We found that in 
IUT-treated patients, afterbirth, the percentages of CD4+ and 
CD8+ T cells as well as B cells were comparable to those in 
the control subjects,
In conclusion, evidence is presented that patients with 
immune hemolytic disease who received IUT therapy 
displayed a significant decrease in NK cell associated mark­
ers in addition to alterations in the activation status of T cells. 
Further analyses of material derived from additional IUT- 
treated patients and control subjects are required to allow 
confirmation of the trends that we detected in this study. The 
observed differences with regard to the development of 
memory T cells and the decrease in NK cells must be inves­
tigated in more detail to unravel the relationship to transfu­
sion therapy and hemolytic disease.
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